Triptorelin
Trelstar · Decapeptyl
FDA-APPROVED · GNRH AGONIST (FDA-APPROVED)
▓ 265 indexed citations across PubMed (152), ClinicalTrials.gov (70), EuropePMC (43).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Background
Triptorelin, sold under the brand name Decapeptyl among others, is a medication that acts as an agonist analog of gonadotropin-releasing hormone, repressing expression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It was patented in 1975 and approved for medical use in 1986. Triptorelin is a therapeutic alternative on the World Health Organization's List of Essential Medicines.
Mechanism of action
Superagonist of GnRH receptor; initial flare then downregulation for medical castration
Researched effects
Prostate cancer; endometriosis; precocious puberty; HPG axis reset
Reported efficacy (trial readout)
-
Lh Suppression Rate 100%
Advances in Therapy (Phase 3, 26wk, n=66)
High confidencen=66Phase 32024 -
Chemical Castration Rate 93.9%
Asia-Pac J Clin Oncol (Phase 4, 39wk, n=109)
High confidencen=109Phase 42024
Trial-efficacy data current as of November 16, 2026.
Live evidence
FDA label safety
4 CONTRAINDICATIONS Known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH. ( 4 ) 4.1 Hypersensitivity TRELSTAR is contraindicated in individuals with a known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH [ see Warnings and Precautions (5.1) ].
Active clinical trials 65
- Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer
- FET in Adenomyosis
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Reported adverse events 3,804
Events spontaneously reported to the FDA FAERS database since 2015. A report does not establish that the drug caused the event, and counts do not reflect how often it occurs. Discuss any concern with a clinician.
FDA FAERS →Recent literature
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
3.75 mg IM depot monthly (Trelstar 1-month label starting dose, also available as 11.25 mg q3mo and 22.5 mg q6mo per Triptodur label); 100 mcg SC single dose (HPG reset off-label)
→ FDA Trelstar (3.75 mg / 11.25 mg / 22.5 mg) and Triptodur (22.5 mg q6mo) prescribing information
Known concerns
Flare (testosterone surge); hot flashes; bone loss long-term
Top-ranked picks
10 pre-curated authoritative sources, ranked by journal tier and study weight.
- GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.
- Efficacy of dual triggering in poor ovarian responders defined according to Bologna and POSEIDON criteria: a systematic review with meta-analysis.
- Comparative effectiveness of luteal phase support strategies in natural cycle frozen-thawed embryo transfer: a systematic review and network meta-analysis.
- Ovulation triggers in unassisted reproduction, an old question still unanswered: a systematic review and meta-analysis.
- Comparison of Luteal Support Protocols in Frozen IVF/ICSI Cycles: A Network Meta-Analysis.
- Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta-analysis.
- Efficacy of progestin-primed ovarian stimulation in women with polycystic ovary syndrome undergoing <i>in vitro</i> fertilization: a systematic review and meta-analysis.
- Effects of fixed-time artificial insemination using triptorelin on the reproductive performance of pigs: a meta-analysis.
- Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation .
- Oocyte maturation triggering in high responders in IVF treatment: a systematic review and network meta-analysis
Full citation library
Year distribution
No references match — clear filters.
Meta-Analyses
10-
1.
This systematic meta-analysis aimed to assess the effectiveness of triptorelin therapy in reducing lower urinary tract symptoms (LUTS) in men with prostate cancer (PCa). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. PubMed, Web of Science and EMBASE databases were searched for studies conducted between 2013 and 2023. Eligible studies included PCa patients undergoing androgen deprivation therapy (ADT) with triptorelin, with reported base…
-
2.
Triptorelin (TRI), a gonadotropin-releasing hormone agonist allowing ovulation synchronization in pigs, is indispensable for fixed-time artificial insemination (FTAI) protocols. However, the effect of FTAI using TRI (FTAI-TRI) on the reproductive performance is controversial. We performed a meta-analysis to determine whether FTAI-TRI affects reproductive performance of pigs, including pregnancy rate (PR), number of pigs born alive per litter (NBA), farrowing rate (FR) and total number of pigs bo…
-
3.
A meta-analysis was undertaken to assess the effect of triptorelin 11.25 mg 3-month prolonged-release formulation in central precocious puberty (CPP). All available clinical studies with triptorelin 11.25 mg were included. The primary outcome was the proportion of children with suppressed luteinising hormone (LH) response (peak LH ≤3 IU/L) to the gonadotrophin-releasing hormone (GnRH) test 3 months after triptorelin 11.25 mg injection. Secondary outcomes included: the proportion with suppressed…
-
4.
<h4>Objective</h4>To evaluate whether ovulation triggers improve pregnancy and/or ovulation rates in women with unexplained or anovulatory infertility undergoing ovulation induction and natural intercourse or intrauterine insemination (IUI), without increasing complications.<h4>Methods</h4>We searched nine databases and grey literature from inception to August 29, 2023. Parallel-group randomized controlled trials (RCTs) including women with unexplained or anovulatory infertility undergoing ovula…
-
5.
This study aimed to conduct computer searches in PubMed, Web of Science, Embase, the Cochrane Library, CNKI, VIP, Wanfang, and CBM databases. Literature was screened and data extracted according to the inclusion and exclusion criteria. RevMan 5.3 was used to assess the methodological quality of the included studies, while Stata 14.0 was employed to rank the efficacy and safety of the five interventions. This analysis included 20 randomised controlled trials involving a total of 2,400 patients. T…
-
6.
<h4>Background</h4>Luteal support is a core success factor of frozen embryo transfers (FET). However, inconsistency across recommended protocols generates notable heterogeneity across reproductive outcomes.<h4>Objective</h4>To determine the most effective luteal support strategy (LPS) based on five key factors related to the effectiveness of FET cycles.<h4>Search strategy</h4>Twelve databases and two prospective registers were searched from inception to 1st January 2024. The study was prospectiv…
- 7.
-
8.
Polycystic ovary syndrome (PCOS) is a common endocrinopathy causing infertility in childbearing women. Progestin-primed ovarian stimulation (PPOS) protocol has recently been used for infertile women. However, whether PPOS provides a significant benefit over gonadotropin-releasing hormone (GnRH) analogue protocols in PCOS is still controversial. The objective of this systematic review is to investigate the efficacy of PPOS in patients with PCOS during <i>in vitro</i> fertilization (IVF) or intrac…
-
9.
<h4>Purpose</h4>To compare dual triggering versus hCG-only triggering in poor responders undergoing controlled ovarian stimulation with a GnRH antagonist protocol in ART cycles.<h4>Methods</h4>A systematic review and meta-analysis was performed. The primary outcome was the number of mature oocytes (MII). The number of oocytes retrieved, clinical pregnancy, and miscarriage rates were analyzed as secondary outcomes. Subgroup analyses were conducted according to the Bologna and POSEIDON classificat…
-
10.
Luteal phase support (LPS) may improve pregnancy outcomes in natural cycle frozen-thawed embryo transfer (NC-FET), though the comparative effectiveness of different regimens remains uncertain. This network meta-analysis (NMA) was conducted as an exploratory synthesis. A systematic search of PubMed, EMBASE, and the Cochrane Library was conducted through March 2026. We performed pairwise meta-analyses using Review Manager 5.3 and exploratory network meta-analyses with Stata 14.0. We assessed certa…
Systematic Reviews
3-
11.
Ovarian cancer is seventh most common cancer in women worldwide. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their life time. The majority of tumours arise from surface of the ovary (epithelial). Two thirds of these women will present with advanced disease, requiring aggressive treatment, which includes debulking surgery (removal of as much disease as possible) and chemotherapy. However, most women (75%) with advanced epithelial ovarian cancer (EOC) wil…
-
12.
To review direct comparative studies of the gonadotrophin-releasing hormone (GnRH) agonists goserelin, triptorelin, and leuprorelin for the treatment of prostate cancer, and identify whether there are meaningful clinical differences between these agents. In June 2017, the following searches were performed independently by two reviewers in PubMed: (i) 'prostate cancer' and 'triptorelin' and 'leuprorelin', (ii) 'prostate cancer' and 'triptorelin' and 'goserelin', and (iii) 'prostate cancer' and 'g…
-
13.
The escalating incidence of prostate cancer poses a significant global public health challenge. Optimal utilization of resources is crucial for the effective deployment of funds among the diverse and emerging treatment options for managing prostate cancer. This systematic review aims to offer insights and serve as a reference for pharmacoeconomic studies related to the use of degarelix and luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of prostate cancer. We conducted a c…
Randomised Controlled Trials
24-
14.
The Hormonal Bone Effects (HOBOE) study tested whether adjuvant triptorelin plus either letrozole (L) or zoledronic acid (Z) plus L (ZL) was more effective than tamoxifen (T) in premenopausal patients with hormone receptor-positive (HR+) early breast cancer (BC). Here we report the long-term follow-up analysis. HOBOE (ClinicalTrials.gov number NCT00412022) is an open-label, three-arm, randomised, phase III trial that involved 16 centres in Italy. One thousand and sixty-five premenopausal patient…
-
15.
To evaluate the efficacy and safety of triptorelin after radical prostatectomy (RP) in patients with negative lymph nodes. PRIORITI (NCT01753297) was a prospective, open-label, randomized, controlled, phase 4 study conducted in China and Russia. Patients with high-risk (Gleason score ≥ 8 and/or pre-RP prostate-specific antigen [PSA] ≥ 20 ng/mL and/or primary tumor stage 3a) prostate adenocarcinoma without evidence of lymph node or distant metastases were randomized to receive triptorelin 11.25 m…
-
16.
This phase 3, randomized, open-label, active-controlled, multicenter study investigated the efficacy of triptorelin pamoate prolonged-release (PR) 3-month in Chinese patients with endometriosis by demonstrating the noninferiority of the 3-month formulation to the standard of care, triptorelin acetate PR 1-month. The trial was conducted in 24 clinical centers in China, and included 300 Chinese women (18-45 years) with endometriosis and regular menstrual cycles who required treatment with a gonado…
-
17.
Limited data exist regarding whether the endocrine response to the gonadotropin-releasing hormone receptor agonist (GnRHa) triptorelin differs in women with polycystic ovary syndrome (PCOS) compared with healthy women or those with hypothalamic amenorrhea (HA). We compared the gonadotropin response to triptorelin in healthy women, women with PCOS, or those with HA without ovarian stimulation, and in women with or without polycystic ovaries undergoing oocyte donation cycles after ovarian stimulat…
-
18.
To compare the endocrine effects of 6 months of adjuvant treatment with letrozole + triptorelin or tamoxifen + triptorelin in premenopausal patients with early breast cancer within an ongoing phase 3 trial (Hormonal Adjuvant Treatment Bone Effects study). Prospectively collected hormonal data were available for 81 premenopausal women, of whom 30 were assigned to receive tamoxifen + triptorelin and 51 were assigned letrozole + triptorelin +/- zoledronate. Serum 17-beta-estradiol (E2), follicle-st…
-
19.
To compare the effect of a GnRH-agonist, triptorelin, versus placebo on the symptoms of endometriosis. A prospective, randomized, double-blind study of 6 months of treatment followed by 12 months of follow-up. Departments of Obstetrics and Gynecology at two universities and one general hospital. Forty-nine women with symptoms of laparoscopically verified endometriosis. Triptorelin depot or placebo was given every 4 weeks. Clinical evaluation, including the Duration Intensity Behavior Scale and V…
-
20.
The study involved 69 patients in whom endometriosis was diagnosed. The patients were divided into three groups randomly. In each of the groups, a different method of treatment was applied. In group A thermocoagulation was used, in group B triptorelin was used and in group C the above monitored methods of treatment were applied. Combined therapy involving the use of both thermocoagulation and triptorelin seen to be the most effective.
-
21.
To compare the efficacy of Dienogest versus Decapeptyl at 3.75 mg as consolidation therapy for surgery in the treatment of endometriosis. Multicenter, open, randomized, parallel-group clinical trial. Volunteer patients in an academic research environment. Women with grade 2, 3, and 4 (</=70) endometriosis at initial laparoscopy. We provided 16 weeks of treatment with Dienogest, 1 mg tablet daily; or with Decapeptyl, 3.75 mg IM injection every 4 weeks. A change in the patient's Revised American F…
-
22.
To compare the i.m. and s.c. routes of depot GnRH agonist administration. Prospective, controlled pharmacokinetics study. Volunteers in an academic research environment. Forty women with benign gynecologic disorders. Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months. Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin. Assessment of side effects, GnRH test results, and triptorelin, LH, FSH, estradiol, and progesterone…
-
23.
To compare the efficacy of monthly administrations of the luteinizing hormone-releasing hormone agonists triptorelin pamoate and leuprolide acetate to induce and maintain castrate levels of serum testosterone in men with advanced prostate cancer. Men with advanced prostate cancer were randomly assigned to receive triptorelin 3.75 mg or leuprolide 7.5 mg. The agent was injected intramuscularly every 28 days for nine injections. Primary endpoints were the percentages of men whose serum testosteron…
-
24.
To determine the dose of triptorelin that is sufficient to maintain complete ovarian suppression in female patients with childhood-onset systemic lupus erythematosus (SLE) who require cyclophosphamide therapy, to determine the length of time needed to achieve ovarian suppression after initiation of triptorelin treatment, and to investigate the safety of triptorelin. In this randomized, double-blind, placebo-controlled, dose-escalation study, female patients ages <21 years were randomized 4:1 to…
-
25.
To find out whether a single-administered GnRH agonist improves the live birth rate in real-life patients undergoing intrauterine insemination (IUI) cycles. A prospective, randomized controlled trial in a public single tertiary center in Tampere University Hospital, Finland. Altogether 251 IUI cycles in 163 patients were randomized to triptorelin and a control group between January 2017 and April 2019. In the triptorelin group, the participants had a single administration of a subcutaneous GnRH…
-
26.
To compare the potency, side effects, and duration of action of triptorelin and leuprorelin acetate after i.m. injections. Prospective, double-blind crossover clinical study. A teaching hospital. Fifty-four patients with pelvic endometriosis. Twenty-seven patients had three doses of i.m. triptorelin (3.75 mg) followed by three doses of i.m. leuprorelin acetate at 4-week intervals. Twenty-one patients had three doses of i.m. leuprorelin acetate (3.75 mg) followed by three doses of i.m. triptoreli…
-
27.
To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until…
-
28.
The addition of a GnRH analogue to the luteal phase in in vitro fertilization programs has been seldom proposed due to the presence of GnRH receptors in the endometrium. The aim of the study was to evaluate the effect of triptorelin addition in short antagonist cycles, compared to cycles where the only supplementation was progesterone. The primary objective of this study was the study of the effect of Triptorelin addiction during the luteal phase on the live birth rate. Secondary objectives of e…
-
29.
Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available. To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin-releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. The PROMISE-GI…
-
30.
Luteinizing hormone-releasing hormone (LHRH) agonists (e.g., triptorelin) reduce ovarian estrogen production in premenopausal women with hormone-sensitive breast cancer. Aromatase inhibitors (e.g., exemestane) inhibit extraovarian production of estrogen and may further reduce circulating estrogens when combined with an LHRH agonist. Healthy premenopausal women were randomized to receive 3.75 mg triptorelin (T) on days 1 and 29 with 25 mg exemestane (EX) or matched placebo once daily for 8 weeks,…
-
31.
Gonadotropin-releasing hormone (GnRH) antagonists for controlled ovarian stimulation (COS) were only recently introduced into China. The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120). The primary end point was the amount of recombinant follicle-stimulating hormone (rFSH) required to meet the human chorion…
-
32.
To compare efficacy of simvastatin with GnRHa (Decapeptyl 3.75 mg) on endometriosis-related pains following surgery for endometriosis. Sixty women with pelvic endometriosis, after laparoscopic diagnosis and conservative laparoscopic surgery, were treated with either simvastatin (n=30) for 16 weeks or Decapeptyl (n=30) every 4 weeks for 4 doses. Using VAS, the score of dyspareunia, dysmenorrhea, and pelvic pain 6 months after laparoscopic surgery declined significantly in both groups (p=0.001), b…
-
33.
To compare the use of two depot GnRH-a, leuprolide and triptorelin, in long-suppression GnRH-a protocols. Prospective, randomized study. An IVF unit of an academic medical center.Fifty-two women who underwent controlled ovarian hyperstimulation and IVF. Patients were prospectively randomized to receive 3.75 mg depot formulations of either leuprolide or triptorelin on days 21-23 of the menstrual cycle. Stimulation with gonadotropins was initiated after pituitary desensitization was achieved. The…
-
34.
In order to assess the feasibility of subcutaneous administration of Triptorelin with 6-week intervals for the suppression of pituitary-gonadal axis and changes of clinical signs in girls with idiopathic central precocious puberty (ICPP), 46 girls with ICPP were treated with GnRHa. Triptorelin (Decapeptyl, 3.75 mg) was administered subcutaneously (SC) at 6-weeks intervals or intramuscularly (IM) at 4-weeks intervals randomly for more than 12 months consecutively. During GnRHa therapy, clinical p…
-
35.
Several lines of evidence suggest that the proliferation of ovarian carcinoma might be stimulated by gonadotrophins. A number of Phase I/Phase II clinical trials have reported that the suppression of endogenous luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone (LHRH) analogs induced objective remissions and/or disease stabilization in 10-30% of patients with advanced refractory ovarian carcinoma. The current study was performed to evaluate wh…
-
36.
To investigate the role of adjuvant treatment with gonadotropin-releasing-hormone agonist (GnRHa) following conservative surgical treatment of endometriosis. Sixty patients in the reproductive age (mean age 28.6 years), with symptomatic stages III and IV endometriosis following laparoscopic surgery and without previous hormonal treatment were enrolled in a prospective, randomized, controlled trial to compare the effects of 3-month treatment with triptorelin depot-3.75 i.m. (30 patients) versus e…
-
37.
To compare the efficacy of danazol and triptorelin (Decapeptyl CR, Ferring, Kiel, Germany) in the management of moderate and severe endometriosis in terms of symptom control and revised American Fertility Society (AFS) score reduction, and to evaluate the hormonal profile of patients treated with triptorelin every 6 weeks. Open and randomized trial. Kwong Wah Hospital, a large public hospital in an urban location (Hong Kong). Forty patients after their first conservative operation for endometrio…
Clinical Trials
14-
38.
This phase 3 study assessed the efficacy, safety, and pharmacokinetics of the 6-month prolonged release (PR) formulation in Chinese children with central precocious puberty (CPP). In this open-label study (NCT05029622), Chinese children (girls < 9 years, boys < 10 years) received two doses of triptorelin pamoate 22.5 mg (day 1 and month 6). Primary endpoint was the proportion at month 6 with luteinizing hormone (LH) suppression (stimulated peak LH ≤ 5 IU/L after gonadotropin-releasing hormone st…
-
39.
To assess whether tibolone can prevent the bone loss and symptomatic side effects normally associated with GnRH agonist (GnRH-a) use and whether tibolone modifies the effect of GnRH-a on endometriosis. Prospective, double-blind, placebo-controlled, group comparative study. Gynecological research unit in a London teaching hospital. Twenty-nine patients with endometriosis and two with fibroids. Six months of treatment with 3.75 mg/mo IM triptorelin combined with daily tablets of either placebo or…
-
40.
To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it with a triptorelin acetate (11.25 mg) 3-month formulation (TA Study). We conducted two phase III, multicentre, single-stage, non-comparative, open-label studies. In the TP Study, patients with CPP received an intramuscular injection of triptorelin pamoate 11.25 mg at baseline and 3 months after baseline. Hor…
-
41.
The impact of treatment of central precocious puberty (CPP) with GnRH agonists on final statural height (FH) remains controversial, and guidelines on the optimal time point for interruption of these treatments have not been established. We analyzed the long term results of 58 girls and 8 boys uniformly treated with triptorelin slow release formulation (Decapeptyl, triptorelin-SR) for CPP and compared their FH with predicted height before treatment and with the FH of a historical group of patient…
-
42.
Uterine leiomyomata alone are an infrequent cause of infertility. We presumed that--since the smaller the uterine size at the time of myomectomy, the greater the chances of subsequent conception--diminishing the preoperative tumor size in infertile patients with large leiomyomata prior to myomectomy should be beneficial. Decapeptyl (D-Trp6-LHRH) depot 3.2 mg was administered for a period of 3-6 months to 23 infertile women. No causes of infertility were found in these patients except for uterine…
-
43.
To compare the efficacy of the oral dienogest versus triptorelin acetate injection for treatment of premenopausal menorrhagia and pelvic pains in women with uterine adenomyosis. A total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited. First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks. Outpatient follow-up was undertaken after 8 weeks b…
-
44.
Triptorelin is an established treatment for central precocious puberty (CPP) as 1- and 3-month formulations. The current triptorelin 22.5 mg 6-month formulation is approved for prostate cancer therapy. This is the first study in patients with CPP. The efficacy and safety of the triptorelin 6-month formulation in CPP were investigated. The primary objective was to evaluate the efficacy in achieving luteinizing hormone (LH) suppression to pre-pubertal levels at month 6. This was an international,…
-
45.
Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
Depot GnRH agonists are commonly used in the treatment of central precocious puberty (CPP). The triptorelin 11.25 mg 3-month depot, currently used in adult indications, had not previously been evaluated in CPP. This was a multicenter, open-label, 12 month trial conducted in 64 CPP children (54 girls and 10 boys), treated quarterly. Children with a clinical onset of pubertal development before the age of 8 years (girls) or 9 years (boys), pubertal response of LH to GnRH > or = 7 IU/l, advanced bo…
-
46.
Estradiol at baseline or after a classical gonadotropin-releasing hormone test did not reflect ovarian steroidogenesis in central precocious puberty (CPP) girls. To evaluate estradiol response to depot triptorelin, both at start and during therapy to determine how active ovarian steroidogenesis is at pubertal stage and under therapy. A prospective study was performed in 43 CPP girls. Serum luteinizing hormone and follicle-stimulating hormone at 3 h (LH-3h, FSH-3h) and estradiol at 24 h (E2-24h)…
-
47.
To evaluate the efficacy and adverse effects of monthly triptorelin injection for the treatment of endometriosis. A multicenter clinical trial including 45 women with endometriosis, treated with triptorelin 3.75 mg i.m. every 4 weeks in six consecutive doses. The main outcome measures were symptom relief, reduction according to revised American Fertility Society (rAFS) scores, reduction in size of ovarian endometrioma, effects on hormone and lipid profiles, changes in bone mineral density (BMD),…
-
48.
Triptorelin 6-month formulation was developed to offer greater convenience to both patients and physicians by reducing the injection frequency. The efficacy, pharmacokinetics and safety of a new 6-month formulation of triptorelin were investigated over 12 months (48 weeks). The primary objective was to evaluate the formulation in achieving castrate serum testosterone levels (< or = 1.735 nmol/L or < or = 50 ng/dL) on day 29 and in maintaining castration at months 2-12. Absence of luteinizing hor…
-
49.
Ninety-five patients with stage C (C1 + C2) or D (D1 + D2) prostatic carcinoma were treated with the long-acting formulation of D-TRP-6 LH-RH (Decapeptyl) for up to 39 months. Of 88 patients evaluable for response, about one-half showed an objective response. In most cases, subjective improvement with relief of bone pain and/or urinary symptoms was obtained. Five patients claimed a mild increase in bone pain and one patient a slight worsening of dysuria following the first injection. Median prog…
-
50.
Men with deviant sexual behavior, or paraphilia, are usually treated with psychotherapy, antidepressant drugs, progestins, and antiandrogens, but these treatments are often ineffective. Selective inhibition of pituitary-gonadal function with a long-acting agonist analogue of gonadotropin-releasing hormone may abolish the deviant sexual behavior by reducing testosterone secretion. In an uncontrolled observational study, we treated 30 men (mean age, 32 years) with severe long-standing paraphilia (…
-
51.
Fourteen patients with advanced ovarian cancer who failed chemotherapy received a long-acting LHRH agonist. All the patients had been previously operated on and all had received at least one regimen of chemotherapy. Duration of decapeptyl administration was between 1 month and 28 weeks. There were no complete or partial responses. Eight patients (57%) had disease stabilization with a median progression-free interval of 14 weeks (range 4-28 weeks). All other patients developed a clear progressive…
Trial Registrations (ClinicalTrials.gov)
70- 52.
-
53.
Conditions: Pregnancy, Embryo Implantation
- 54.
- 55.
- 56.
-
57.
Conditions: Prostatic Neoplasms
-
58.
Conditions: Prostate Cancer
-
59.
Conditions: Unexplained Infertility
-
60.
Conditions: Infertility
-
61.
Conditions: Metastatic Castration-sensitive Prostate Cancer
- 62.
-
63.
Conditions: Idiopathic Short Stature
-
64.
Conditions: Prostate Cancer
-
65.
Conditions: Castration-resistant Prostate Cancer Patients with Oligometastases
-
66.
Conditions: Prostate Cancer
-
67.
Conditions: Advanced Prostate Cancer, Metastatic Prostate Cancer, Locally Advanced Prostate Cancer
-
68.
Conditions: Breast Cancer, Osteoporosis
-
69.
Conditions: Prostate Cancer
-
70.
Conditions: Prostate Adenocarcinoma
-
71.
Conditions: Poor Responders, IVF, Clomiphene Citrate (+2)
-
72.
Conditions: IVF, Luteal Phase Defect
- 73.
-
74.
Conditions: Prostatic Neoplasms
-
75.
Conditions: IVF, LOW OVARIAN RESPONSE
- 76.
-
77.
Conditions: Triple Negative Breast Cancer, Premenopausal Breast Cancer
-
78.
Conditions: Prostate Cancer
-
79.
Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer (+1)
-
80.
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 (+2)
-
81.
Conditions: Metastatic Castration-resistant Prostate Cancer
-
82.
Conditions: Prostatic Neoplasm
-
83.
Conditions: Infertility, Female
- 84.
-
85.
Conditions: Effect of Adding GnRHa as Luteal Phase Support in Antagonist ART Cycles
-
86.
Conditions: Prostate Cancer
-
87.
Conditions: Infertility, Premature Ovarian Failure
- 88.
-
89.
Conditions: Infertile High-risk Patients With Polycystic Ovaries
-
90.
Conditions: Polycystic Ovary Syndrome
-
91.
Conditions: Prostate Cancer
-
92.
Conditions: The Neoadjuvant Therapy
-
93.
Conditions: Infertility, Poor Ovarian Response
-
94.
Conditions: Recurrent Prostate Cancer
-
95.
Conditions: Endometriosis
- 96.
-
97.
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence (+3)
-
98.
Conditions: Deep Infiltrating Endometriosis (DIE), Infertility
- 99.
-
100.
Conditions: ICSI, IVF, Normal Responders (+5)
-
101.
Conditions: Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic (+2)
-
102.
Conditions: Prostate Cancer, mHSPC, mCRPC
-
103.
Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation (+2)
- 104.
-
105.
Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
-
106.
Conditions: Fertility Preservation
- 107.
-
108.
Conditions: Adenomyosis
-
109.
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer (+2)
- 110.
-
111.
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
-
112.
Conditions: Low Ovarian Reserve, Poor Ovarian Response
- 113.
-
114.
Conditions: Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer (+1)
-
115.
Conditions: Prostate Cancer, Prostate, Prostate Cancer Patients
-
116.
Conditions: Fertility
-
117.
Conditions: Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma (+5)
-
118.
Conditions: Breast Cancer Invasive Nos
-
119.
Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma (+1)
-
120.
Conditions: Prostate Cancer, Localized Prostate Carcinoma
- 121.
Reviews
21-
122.
A 6-month formulation of the gonadotropin-releasing hormone agonist triptorelin embonate (designed to deliver 22.5 mg of triptorelin over a 6-month period) has been developed for use in the treatment of advanced prostate cancer. Following intramuscular administration of the 6-month formulation of triptorelin embonate 22.5 mg to men with advanced prostate cancer (subset of 15 patients from the pivotal clinical trial), serum testosterone levels initially increased, followed by a rapid, sustained d…
-
123.
Over the past 30 years, gonadotropin-releasing hormone agonists (GnRH-a) have been used to induce a hypoestrogenic status in women with endometriosis with the aim to cause an improvement in pain symptoms similar to that observed after menopause. Triptorelin is one of the most commonly used GnRH-a. This review offers an explanation of the mechanism of action, of the pharmacokinetics and pharmacodynamics of triptorelin and gives the readers a complete overview of the studies on the clinical effica…
-
124.
Triptorelin depot is largely used to treat central precocious puberty (CPP) in children. Areas covered: This review updates triptorelin depot treatment of CPP, focusing on trials that compared 3.75 mg/28 day treated and untreated children till the adult height (AH). Efficacy of the new 11.25 mg/90 days or 22.5 mg/6 month formulations in suppressing pituitary-gonadal axis in short-term trials is also addressed. Short- and long-term safety was summarized. Expert commentary: Long experience on trip…
-
125.
A 1-month formulation of the gonadotrophin-releasing hormone agonist (GnRHa) triptorelin (Decapeptyl
- 126.
-
127.
Triptorelin, a synthetic gonadotropin-releasing hormone (GnRH) agonist, has garnered increasing attention for its profound effects on endocrine profiles across diverse populations. This review article explores triptorelin's impact on women's health by examining its effects on healthy individuals, those with polycystic ovary syndrome (PCOS), and those experiencing hypothalamic amenorrhea (HA). The mechanism of triptorelin involves a transient surge in gonadotropin release, followed by receptor de…
-
128.
Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally advanced and metastatic prostate cancer, and aims to reduce testosterone to levels obtained by surgical castration. Use of gonadotropin-releasing hormone (GnRH) agonists predominates among the ADT options. The GnRH agonist, triptorelin is a first-line hormonal therapy that has demonstrated efficacy and safety in clinical trials of patients with locally advanced non-metastatic or metastatic disease. Susta…
-
129.
GnRH agonists are derived from the native molecule by substitution of a D-amino acid in position 6 which increases their resistance to enzymatic breakdown and their affinity for LH-RH receptors in comparison with the native hormone. Because of this improved resistance which increases their half-life they have a super-agonistic effect. In 1973, two years only after he characterized LH-RH, A.V. Schally synthesized several GnRH analogs, including D-TRP6-LHRH obtained by substituting the glycine-6 w…
-
130.
Several methodological problems complicate the evaluation of final statural height (FH) benefit after treatment with gonadotropin releasing hormone (GnRH) agonists for central precocious puberty (CPP). Since no controlled study has been performed, we have to rely on indirect methods, comparison with predicted height or with historical controls. FH of 58 girls, uniformly treated with triptorelin slow release formulation (triptorelin-SR, Decapeptyl((R))) for CPP were compared with predicted height…
- 131.
-
132.
Among the therapies to achieve medical castration, gonadotropin-releasing hormone (GnRH) agonists have better safety profiles than estrogens and anti-androgens. In addition, slow-release formulations of GnRH agonists offer patients flexibility, improve quality of life and eventually reduce cost. To illustrate the role of medical castration in prostate cancer, this paper reviews data on the GnRH agonist triptorelin long-duration and shorter-duration formulations. A similar proportion of patients…
-
133.
Studies of gonadotropin-releasing hormone analogues (intramuscular [IM] leuprolide acetate [LA] and triptorelin) for treatment monitoring of central precocious puberty (CPP) demonstrate this approach is effective for confirming pubertal hormone suppression. Herein, we provide new data using subcutaneous LA (SC LA), suggesting similar efficacy for treatment monitoring. PubMed, Embase, and CINAHL were searched for studies of GnRHa used to monitor treatment of CPP. The titles and the abstracts were…
-
134.
Since 2018, the Italian National Committee for Bioethics (CNB) has endorsed the off-label use of triptorelin, a gonadotropin-releasing hormone agonist (GnRHa), for managing adolescent gender dysphoria (GD). Administered to suppress puberty, triptorelin provides adolescents time to explore their gender identity without the distress of developing secondary sexual characteristics. However, concerns persist regarding its long-term effects on bone density, brain development, and fertility. Ethical de…
-
135.
Endocrine treatment represents the cornerstone of endocrine-sensitive premenopausal early breast cancer. The estrogen blockade plays a leading role in the therapeutic management of hormone receptor-positive breast cancer together with surgery, radiotherapy, and selective antiestrogen treatments. For several years, selective estrogen receptor modulators, such as tamoxifen, have represented the mainstay of therapy. The role of amenorrhea has been extensively elucidated in the past year: the benefi…
-
136.
Because of the limits of justice, our society turns itself towards the medical need and demands efficient treatments. Mutilating neuro-surgery and treatment with estrogens have been used and then stopped. Medroxyprogesterone (MPA) and Cyproterone (CPA) acetate have been proved to be efficient in 80% of cases studied and published. However the therapeutic use of CPA is limited in France by three drawbacks: exclusive oral route of administration, lack of available biological criteria as a control…
-
137.
Luteinizing hormone releasing hormone (LH RH) agonists are the major agent for androgen deprivation therapy in advanced and metastatic prostate cancer. They also have a role in endometriosis, uterine fibroids and central precocious puberty. Triptorelin embonate 22.5 mg is a new, sustained-release, 6-month formulation of an LH RH agonist. It possesses longer duration of action than the current standard 3-month preparation and appears to have similar efficacy and side effects. The use of LH RH ago…
-
138.
In patients with non-localised prostate cancer, medical castration is generally achieved with a GnRH agonist such as triptorelin. A peripheral antiandrogen can be added during the first weeks of treatment to counteract the initial testosterone surge. Degarelix is the first GnRH antagonist to be authorised in this setting in the European Union. A randomised unblinded trial compared subcutaneous degarelix versus intramuscular leuprorelin, without the addition of a peripheral antiandrogen. Castrati…
-
139.
Chronic administration of luteinizing hormone-releasing hormone (LH-RH) is currently considered as the most appropriate therapy of precocious puberty. A delayed release preparation of D-Trp-6-LH-RH (Décapeptyl in microcapsules) designed to release the agonist for 28 days after intramuscular injection of 60 micrograms/kg body wt was given to 12 boys and 26 girls with precocious puberty. Plasma levels of gonadotropins and sex steroids were suppressed to prepubertal levels within 3 weeks, whilst pi…
-
140.
Efficacy and safety of a superactive gonadotrophin-releasing hormone analogue (D-Trp-6-LHRH, decapeptyl) was assessed in seven girls, aged two to seven years with precocious puberty (four idiopathic, two associated to McCune-Albright syndrome and one with myelomeningocele). A further case of a seven year old male was treated with a delayed release formulation of the analogue combined with cyproterone acetate for the first two weeks of therapy. Three cases had previously been unsuccessfully treat…
-
141.
The procedures used for programming and ovarian stimulation in GIFT are identical to those used for in-vitro fertilization. At the Baudelocque Hospital, the hypophyseal gonadal axis is suppressed by administering a gonadotrophin-releasing hormone analogue (Decapeptyl, D-Trp-6-LHRH). Programming for the week of GIFT is then possible by controlling three stages: the beginning of treatment, which is independent of the date of the patient's period, the duration of treatment, which has 5 days' maximu…
-
142.
Triptorelin, a GnRH analogue, is used as a puberty blocker for transgender and gender-diverse adolescents experiencing gender dysphoria (GD). This treatment allows these individuals to delay puberty, offering time to explore their gender identity. Despite its recognized benefits in alleviating psychological distress, there are concerns regarding its side effects and the adequacy of psychological support during treatment. The article examines the use of triptorelin in treating GD, focusing on its…
Research Articles
113- 143.
-
144.
Poly(lactide-co-glycolide) (PLGA) is the key component of long acting drug products responsible for providing sustained release in a controlled manner. The objective of the current study was to develop and validate an analytical protocol to determine key properties of PLGA used in commercial long-acting drug products. Procedures to isolate PLGA from commercial products have been established and the key properties of PLGA, such as polymer molecular weight, lactide:glycolide (L:G) ratio, and natur…
-
145.
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. This study aimed to characterize the real-world adverse event(AE) profile associated with triptorelin using data from the FDA Adverse Event Reporting System(FAERS). We conducted a retrospective pharmacovigilance study utilizing FAERS reports from the first quarter…
-
146.
The effects of triptorelin (Decapeptyl) and heparin, alone or in combination, on the intracellular concentration of estradiol (E2) after incubation of estrone sulfate (E1S) with the MCF-7 mammary cancer cells was investigated. Although heparin (10 mg/l culture medium) or Decapeptyl (5 x 10(-7) or 5 x 10(-5) mol/l) did not affect the levels of radioactive E2 after incubation with [3H]E1S, the combination of Decapeptyl and heparin significantly decreased the radioactive uptake and the intracellula…
-
147.
Triptorelin is a first-line drug for assisted reproductive technology (ART), but the low bioavailability and frequent subcutaneous injection of triptorelin impair the quality of life of women preparing to become pregnant. We report silk fibroin (SF)-based microneedles (MNs) for transdermal delivery of triptorelin-loaded nanoparticles (NPs) to improve bioavailability and achieve safe and efficacious self-administration of triptorelin. Triptorelin was mixed into an aqueous solution of SF with shea…
- 148.
-
149.
There is still no consensus on simple methods to monitor the effectiveness of gonadotropin-releasing hormone analogs in girls with precocious or early puberty. To evaluate the value of urinary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) before and after triptorelin stimulation test detected by immunochemiluminometric assay (ICMA) to monitor the efficacy of triptorelin depot in girls with precocious or early puberty. A total of 128 girls with precocious or early puberty were i…
-
150.
Precocious puberty (PP) in girls is defined by thelarche before age 8. The diagnostic gold standard is an increased LH level following gonadotropin-releasing hormone (GnRH) stimulation. Alternatively, GnRH analogues like triptorelin can be used, though their interpretation varies. Since 2000, we have used a triptorelin-induced LH cut-off of 15 IU/L, 4 h post-stimulus. However, many girls showed LH values below this threshold despite evident pubertal progression. To establish a new LH threshold p…
-
151.
Gonadotropin-releasing hormone (GnRH) is a reproductive key hormone. The GnRH analogues are widely used in in vitro fertilization and treatment of sex hormone-depended cancers induced by the materials used in chemotherapeutic agents. The aim of this study is to evaluate the effects of cyclophosphamide and decapeptyl (analogues of GnRH) on histomorphometry and stereology of testicular tissue as well as gonadotropic and gonadal hormones indices in mice. For this study, 24 adult male Balb/C strain…
-
152.
Central precocious puberty (CPP) results from premature activation of hypothalamic-pituitary-gonadal axis, with the consequent increase of gonadotropin-releasing hormone (GnRH); GnRH agonists (GnRHa) represent the gold-standard therapy in children with CPP although their use might be responsible for pituitary GnRH receptors down-regulation, that in turn suppresses luteinizing hormone (LH) and follicle stimulating hormone (FSH) and blocks of gonadal sex hormones release. The most prescribed GnRHa…
-
153.
The gold standard gonadotropin-releasing hormone (GnRH) stimulation test uses the response to intravenously injected gonadorelin to diagnose central precocious puberty (CPP). However, gonadorelin is not always readily available. This study investigated the diagnostic efficacy of the subcutaneous triptorelin test and the optimal blood sampling time for diagnosis of CPP. This study retrospectively examined the medical records of 220 girls who had undergone either the triptorelin or gonadorelin tes…
-
154.
The effects of depot formulations of the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl (25 microg/day) for 30 days or LHRH antagonist Cetrorelix pamoate (100 microg/day) for 30 days and daily injections of 100 microg of Decapeptyl for 10 days on the expression of mRNA for pituitary LHRH receptor (LHRH-R) and the levels of LHRH-R protein were evaluated in rats. Serum sex steroid concentrations and the weights of the reproductive organs were greatly reduced in all groups treated…
-
155.
More than 80% of human ovarian cancers express LHRH and its receptor as part of a negative autocrine mechanism of growth control. This study was conducted to investigate whether LHRH affects apoptosis in ovarian cancer. EFO-21 and EFO-27 ovarian cancer cells were treated with LHRH agonist Triptorelin or with cytotoxic agent Doxorubicin in the absence or presence of Triptorelin. Apoptotic cells were quantified by flow cytometry. Expression of nuclear factor kappa B (NFkappaB) was assessed by RT-P…
-
156.
The effects of the polypeptide Decapeptyl (a gonadotropin-releasing hormone (GnRH) agonist analogue) and of transforming growth factor-alpha (TGF-alpha), on estrone sulfate-sulfatase activities in the homogenates of various breast cancer cell lines were studied in the presence of heparin. In hormone-dependent MCF-7 breast cancer cells, Decapeptyl can inhibit sulfatase activity, and this effect is significantly augmented in the presence of heparin. In the other hormone-dependent T-47D breast canc…
-
157.
Triptorelin is available as 1- and 3-month prolonged-release (PR) formulations; at the time of the study, only the former was approved for central precocious puberty (CPP) in China. This study assessed the efficacy and safety of the triptorelin 3-month PR formulation in Chinese children with CPP. In this 12-month, prospective, open-label, multicentre, single-arm study (NCT04736602), Chinese children (mean age [standard deviation (SD)], 7.6 ± 0.8 years) with CPP received triptorelin pamoate 15 mg…
-
158.
The role of midluteal phase gonadotropin-releasing hormone (GnRH) agonist had been an issue of debate. The aim of this retrospective study was to evaluate the effect of a mid-luteal phase GnRH agonist as an additional luteal phase support (LPS) in patients receiving intracytoplasmic sperm injection (ICSI). Additionally, we elucidate which subgroup would gain the most benefit from GnRH agonist as LPS. The medical records were retrieved from January 2009 to January 2012 and a total of 348 patients…
-
159.
Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment. In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or tri…
- 160.
-
161.
Triptorelin and leuprorelin are synthetic gonadotrophin-releasing hormones (GnRH) that are on the World Anti-Doping Agency (WADA) list of prohibited substances. To investigate the possible in vivo metabolites of triptorelin and leuprorelin in humans compared to previously reported in vitro metabolites, excreted urine from five patients treated with either triptorelin or leuprorelin was analyzed by liquid chromatography coupled with ion trap/time-of-flight mass spectrometry (LC/MS-IT-TOF). The ad…
-
162.
Most of the northern hemisphere donkey breeds are faced with the risk of extinction, thus donkey reproduction is considered an emerging branch of theriogenology, and the management of artificial insemination and induction of ovulation is a crucial point in setting up preservation protocols. For four consecutive cycles, six jennies' ovarian activity was routinely monitored; an ultrasound examination was performed daily from the evidence of a follicle diameter ≥27 mm until ovulation. Upon reaching…
-
163.
The aim of this study is to compare the clinical and biochemical outcomes of triptorelin acetate (TPA) versus triptorelin pamoate (TPP) treatment in girls with central precocious puberty. A total of 60 patients with idiopathic CPP were retrospectively recruited. Thirty girls were treated with triptorelin acetate 3.75 mg/month (TPA group) and thirty girls in a second group received triptorelin pamoate 3.75 mg/4 weeks (TPP group). Patient follow-up at 12 and 24 months included GnRH Test at 12 mont…
-
164.
Luteinising hormone-releasing hormone agonist (LHRHa) injections are currently used in the treatment of advanced prostate cancer, but the frequency of injections may represent a burden to patients and healthcare services. The aim of this study was to collect real-world evidence about clinical and practical outcomes for patients with prostate cancer initiating six-monthly triptorelin, or switching from shorter-acting formulations to six-monthly triptorelin, in hospitals in the DEcapeptyl SERVice…
-
165.
The gonadotropin-releasing hormone (GnRH) stimulation test is the gold standard for diagnosing central precocious puberty (CPP). Gonadorelin (Relefact) is used for the test but is not always readily available; triptorelin is used as an alternative. The purpose of this study was to evaluate the diagnostic validity of the triptorelin test compared with the GnRH test in the diagnosis of CPP in girls. This retrospective study included 100 girls with premature thelarche (PT) who underwent a hypothala…
-
166.
Fixed-time artificial insemination is an important technique in swine production that can improve reproductive efficiency and meat production quality through making better use of the genetic potential of breeding males and reducing the costs associated with double or multiple inseminations. Our goal was to evaluate the vaginal application of the GnRH agonist triptorelin acetate to synchronize ovulation in post-weaning sows and facilitate the implementation of a single, fixed-time insemination. I…
-
167.
Gonadotropin-releasing hormone (GnRH) stimulation test is the gold standard for diagnosing central precocious puberty (CPP). However, intravenous GnRH is not always readily available. The aim of the present study was to evaluate the diagnostic accuracy of triptorelin-stimulated luteinizing hormone (LH) concentrations in the diagnosis of CPP among girls presenting with premature thelarche compared to the gold standard GnRH test. A prospective, case-control (CPP vs isolated premature thelarche), c…
-
168.
To evaluate the efficacy of 24-weekly Decapeptyl SR (Triptorelin) treatment, compared with the 12-weekly regimen, in children with central precocious puberty (CPP). A multicentre retrospective cohort study was conducted on patients with CPP treated with gonadotropin-releasing hormone analogue (GnRHa) therapy between September 2008 and December 2024. Participants were recruited from three tertiary paediatric endocrinology centres in the UK: the Royal London Hospital (Barts Health NHS Trust), Shef…
-
169.
The antiproliferative effect of two GnRH agonists (leuprorelin acetate and triptorelin), alone or combined with tamoxifen (TAM) or medroxyprogesterone acetate (MPA), on human estrogen-sensitive endometrial cancer cells (Ishikawa) was investigated. Although ineffective when tested alone in all the culture conditions used, both analogues counteracted or even suppressed the estrogen-stimulated growth of Ishikawa cells. The antiestrogenic effect of TAM or MPA was not modified by their association wi…
- 170.
-
171.
The intramuscular (i.m.) administration of Decapeptyl Depot has been approved in Germany for the treatment of advanced hormone dependent prostate cancer since July 1990. In this study a reformulated Decapeptyl Depot, administered as a first-line endocrine therapy, was injected intramuscularly (i.m.) or subcutaneously (s.c.) every 28 days for 6 months. At 12 different hospitals, 52 prostate cancer patients were treated, whereby 25 patients received a s.c. injection and 27 patients a i.m. injectio…
-
172.
The long-term follow-up in children with familial male-limited precocious puberty (FMPP) who were treated with letrozole, triptorelin, and spironolactone is limited, especially considering the efficiency and safety. We describe the clinical characteristics and long-term treatment with letrozole on adult height of a boy diagnosed with FMPP, confirmed by analysis of the LHCGR gene. Physical examinations, bone age (BA), testosterone, and gonadotropin levels were measured as well as gene sequencing…
-
173.
Regulation of ovarian folliculogenesis involves bidirectional communication between the immune and endocrine systems. Somatostatin analogues have been reported to acutely suppress elevated androgens in polycystic ovary syndrome (PCOS). The aim of our study was to analyze the morphologic and hormonal-metabolic response to octreotide therapy for one month in insulin-resistant PCOS patients in whom luteinizing hormone (LH) effect had formerly been separated by a six-month GnRH-agonist (GnRH-a) cour…
- 174.
-
175.
Recently, GnRH antagonists (GnRHant) like cetrorelix and ganirelix have been introduced in protocols of controlled ovarian hyperstimulation for assisted reproductive techniques to prevent premature luteinizing hormone (LH) surges. Here we tested, whether the actions of cetrorelix and the GnRH agonist (GnRHag) triptorelin in gonadotrophs are dependent on the steroid milieu. Furthermore, we characterized the actions of cetrorelix and triptorelin on LH secretion and the total LH pool. Female rat pi…
-
176.
There is an ongoing debate about the optimal dosage of gonadotropin-releasing hormone (GnRH) agonist for oocyte triggering in polycystic ovarian syndrome (PCOS) patients at risk for ovarian hyperstimulation syndrome (OHSS). In this study, we intend to ascertain whether the use of repeated doses of a GnRH agonist for oocyte triggering in these patients can enhance the outcomes of controlled ovarian stimulation (COS) for This randomised clinical trial enrolled 70 PCOS women candidates for IVF/ICSI…
-
177.
Estrogens (estrone [E1] and estradiol [E2]), their sulfates and progesterone receptor (PR) were evaluated in patients with uterine leiomyomata nontreated and treated with Decapeptyl (D-Trp6-gonadotropin-releasing hormone [GnRH]; Ipsen Biotech, Paris, France). Estrogen concentrations are very high in the leiomyoma (secretory phase, pg/g tissue [mean +/- SEM]: n = 10; E1: 147 +/- 24; E2: 850 +/- 116; E1-sulfate: 1,668 +/- 808; E2-sulfate: 718 +/- 126). Decapeptyl treatment provokes a significant d…
-
178.
A newly generic microspheres, sustained-release formulation of triptorelin acetate 3.75 mg has been developed. To evaluate the efficacy, pharmacokinetics, and safety of triptorelin 1-month formulation in Chinese patients with prostate cancer. An open-label, multicenter clinical trial with one arm testing a 1-month sustained-release triptorelin formulation in prostate cancer patients. Patients with prostate cancer received three consecutive 28-day injections of triptorelin acetate. The primary en…
-
179.
In order to study its effect on pituitary and ovarian function, a single dose of triptorelin depot (Decapeptyl CR, Ferring) was administered to 12 women in the early follicular (EF,n = 6) or mid-luteal phase (ML,n = 6) of a normal cycle. In all 12 women the initial pituitary and ovarian responses were similar. Luteinizing hormone (LH) and follicle stimulating hormone (FSH) rose to peak values within 48 h, and declined to hypogonadotropic levels within 2 weeks' time. Steroid levels showed a sligh…
-
180.
Recently, development of multifunctional contrast agent for effective targeted molecular computed tomography (CT) imaging of cancer cells stays a major problem. In this study, we explain the ability of Triptorelin peptide-targeted multifunctional bismuth nanoparticles (Bi2S3@ BSA-Triptorelin NPs) for molecular CT imaging. In this experimental study, the formed nanocomplex of Bi2S3@ BSA-Triptorelin NPs was characterized using different methods. The MTT cytotoxicity test was performed to determine…
-
181.
The Food Safety Commission of Japan (FSCJ) conducted a risk assessment of triptorelin acetate (CAS No. 140194-24-7), which is intended for use in a single fixed-time insemination by synchronizing estrus cycles of weaned sows, based on the documents for the import tolerance application. FSCJ recognize none of adverse effects of triptorelin acetate on human health through dietary exposure, because of the lack of genotoxicity relevant to human health and negligible oral bioavailability due to the d…
-
182.
A double-layer silk fibroin microneedles (SF-MNs) was proposed for the transdermal delivery of triptorelin. Two-step pouring and centrifugation were employed to prepare SF-MNs. Triptorelin was wrapped in MNs in the form of microcrystals with a size of ∼1 μm. β-sheet nanocrystals (the secondary structure of silk fibroin) were adjusted in content by methanol-vapor treatment to manipulate the characteristics of SF-MNs prepared with two concentrations of silk fibroin. The mechanical strength of MNs…
-
183.
A large majority of tumors of the reproductive system express the gonadotropin releasing hormone receptor (GnRHR). Blockade and activation of this receptor with various antagonistic and agonistic analogues of native GnRH-I (pGlu(1)-His(2)-Trp(3)-Ser(4)-Tyr(5)-Gly (6)-Leu(7)-Arg(8)-Pro(9)-Gly(10)-NH2), respectively, has shown efficient suppression of tumor growth. In this study, the GnRH-receptor system has been evaluated with respect to its suitability as a target for in vivo peptide receptor ta…
-
184.
This study aimed to distinguish isolated hypogonadotropic hypogonadism (IHH) from constitutional delay in growth and puberty (CDGP) by various hormonal tests in both sexes. Boys with testicular volume (TV) <4 ml (14-18 years) and girls with breast B Of 34 children (male: 22 and female: 12), CDGP and IHH were diagnosed in 21 and 13 children, respectively. 4 hours post-triptorelin LH had the highest sensitivity (100%) and specificity (100%) for identifying IHH in both sexes. Basal inhibin B had go…
-
185.
Central precocious puberty (CPP) results from premature activation of the hypothalamic-pituitary-gonadal axis. The GnRH stimulation test remains the diagnostic gold standard, especially in girls with undetectable basal LH levels. However, native GnRH is expensive and often unavailable. Rapid-acting subcutaneous triptorelin has been proposed as a reliable alternative. This retrospective study evaluated the diagnostic accuracy of subcutaneous triptorelin compared with intravenous gonadorelin and i…
-
186.
Triptorelin, a long-acting gonadotropin-releasing hormone (GnRH) agonist, is available in 1-, 3-, and 6-month formulations to treat central precocious puberty (CPP). The triptorelin pamoate 22.5-mg 6-month formulation recently approved for CPP offers greater convenience to children by reducing the injection frequency. However, worldwide research on using the 6-month formulation to treat CPP is scarce. This study aimed to determine the impact of the 6-month formulation on predicted adult height (…
-
187.
The aim of this study was to assess the efficacy of different doses of buserelin acetate and another GnRH agonist, triptorelin acetate, in saline solution in a single subcutaneous injection, to induce ovulation of growing pre-ovulatory follicle in mare and compare it with the classical treatment of a single injection of hCG. The study is split into 3 experiments over different breeding seasons in the same stud with a random distribution of treatment. The first one was to compare the injection of…
-
188.
Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study.
Data on modalities of real-world use of androgen deprivation therapy, such as triptorelin, in men with prostate cancer (PCa) are lacking. To describe the real-world management of triptorelin treatment over 12 months following treatment initiation in France, and to gain a better understanding of the choices being made about planned total treatment duration, formulation, and route of administration. TALISMAN was a prospective, multicenter, longitudinal, non-interventional study. Patients with PCa…
-
189.
Triptorelin is one of the most commonly used gonadotropin-releasing hormone agonists and has been used in the treatment of deep infiltrating endometriosis (DIE). This study aimed to evaluate the efficacy and safety of up to 24 weeks of triptorelin treatment after conservative surgery for DIE.This prospective, non-interventional study was performed in 18 tertiary hospitals in China. Premenopausal women aged ≥18 years treated with triptorelin 3.75 mg once every 28 days for up to 24 weeks after con…
-
190.
This study was focused on the pattern of LH release from the pituitary during the initial response to high dose GnRH agonist administration. Secondly, the pattern of LH release and the pituitary responsiveness to physiological and pharmacological stimulation during long-term pituitary suppression by a high dose GnRH agonist was studied. In addition, the relation between serum agonist levels and pituitary function and responsiveness was investigated. DTrp6GnRH in microcapsules (Decapeptyl CR) was…
-
191.
This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy and its effects on LUTS were evaluated focusing on symptom relief and changes in quality of life (QOL) related to urinary symptoms (November 2006 to May 2010). Inclusion criteria were age >18 years, histologically confirmed advanced or m…
-
192.
The understanding of adhesive interaction at the nanoscale between functionalized nanoparticles and biological cells is of great importance to develop effective theranostic nanocarriers for targeted cancer therapy. Here, we report a combination of experimental and computational approaches to evaluate the adhesion between Triptorelin (a Luteinizing Hormone-Releasing Hormone (LHRH) agonist)-conjugated poly-(ethylene glycol) (PEG)-coated magnetite nanoparticles (Triptorelin-MNPs) and breast cells.…
- 193.
-
194.
Triptorelin acetate was encapsulated into silica microparticles by spray-drying a mixture of colloidal silica sol and triptorelin acetate solution. The resulting microparticles were then combined with another silica sol containing silica nanoparticles, which together formed an injectable silica-triptorelin acetate depot. The particle size and surface morphology of the silica-triptorelin acetate microparticles were characterized together with the in vitro release of triptorelin, injectability and…
- 195.
-
196.
To evaluate the effectiveness of triptorelin for the treatment of adenomyosis, the benign invasion of endometrial tissue into the myometrium, as a fertility-preserving alternative to the gold standard hysterectomy. In this multicenter, open-label, observational study in Russia, performed from November 3, 2011, to August 24, 2015, we assessed the efficacy and safety of triptorelin 3.75 mg administered intramuscularly every 28 days in Russian women who were gonadotropin-releasing hormone agonist t…
-
197.
Type I gonadotropin-releasing hormone (GnRH-I) agonists have been applied for the treatment of steroid-dependent tumors such as breast carcinoma, ovarian cancer and prostatic carcinoma. But the mechanism has not been clarified yet. There are few reports about the treatment of endometrial carcinoma using GnRH-I agonists. Type II GnRH (GnRH-II) is a new subtype of GnRH. Our aim was to investigate the effects of GnRH-I agonists and GnRH-II on estrogen receptor-negative human endometrial carcinoma c…
-
198.
Triptorelin, a gonadotropin-releasing hormone agonist, has been used in the treatment of hormone-responsive prostate cancer by inducing testosterone suppression. Research on the relationship between the time courses of triptorelin and testosterone is very important, but accurate quantification of triptorelin and testosterone simultaneously in biological specimens is a challenging analytical problem. In the present study, a rapid, sensitive, and selective method for simultaneous determination of…
-
199.
To investigate the diagnostic value of urine luteinizing hormone (ULH) after the triptorelin stimulation test detected by immunochemiluminometric assay (ICMA) in girls with central precocious puberty (CPP). The girls with precocious puberty were included. The triptorelin stimulation test at 8:30 a.m. was performed. Two consecutive 12-hour urine samples were collected after the test, defined as the first 12-hour and second 12-hour urine, respectively. ICMA measured ULH. Urine creatinine (Cr) conc…
-
200.
Triggering final oocyte maturation is a key step of ovarian stimulation. Although previous studies demonstrated a negative association between female BMI and serum hCG levels, little evidence is available regarding the association between oocyte yield and patients' BMI. The scope of the current study was to examine whether the efficiency of the r-hCG and triptorelin to trigger final oocyte maturation may be associated with patients' BMI or weight. This is a retrospective observational study incl…
-
201.
One of the common side effects of chemotherapy drugs is ovarian failure and uterine dysfunction, which can occur after the administration of doxorubicin and/or cyclophosphamide. In clinics, gonadotropin-releasing hormone agonists (GnRHa) are used to modulate the toxic effect of chemotherapy and intercept infertility with some controversy and limited histological knowledge. This study aimed to evaluate the serological and histological features of protective effects of triptorelin, (GnRHa), on ute…
-
202.
The effects of pituitary suppression with one-third depot of long-acting gonadotropin-releasing hormone (GnRH) agonist in GnRH agonist long protocol for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) were investigated. A retrospective cohort study was performed on 3186 cycles undergoing IVF/ICSI with GnRH agonist long protocol in a university-affiliated infertility center. The pituitary was suppressed with depot triptorelin of 1.25 mg or 1.875 mg. There was no significant d…
-
203.
Increasing research has been focused on the development of various nanocomplexes as targeted contrast media in diagnostic modalities, mainly in computed tomography (CT) scan imaging. Herein, we report a new method that uses Triptorelin [a luteinizing hormone-releasing hormone (LHRH) agonist]-targeted gold nanoparticles (AuNPs) via alginate for early detection of cancer by molecular CT imaging. In the experimental study, the formed multifunctional AuNPs coated with alginate conjugated with Tripto…
-
204.
The peripheral benzodiazepine receptor (PBR) is composed of three subunits with molecular masses of 18, 30, and 32 kDa. Many physiological functions have been attributed to the PBR, including regulation of steroidogenesis. Furthermore, the PBR itself is under hormonal regulation. In the current study, we investigated the role of female gonadal sex hormones in the regulation of PBR expression in steroidogenic and nonsteroidogenic tissues. To accomplish this, adult female rats were pharmacological…
-
205.
Although triptorelin is increasingly used in China for biochemical castration, its effects on primary prostate cancer symptoms remain unclear. This study aimed to assess the prevalence of lower urinary tract symptoms (LUTS) in Chinese prostate cancer patients and the effectiveness of triptorelin on LUTS. In this 48-week multicenter, non-interventional, prospective study, we enrolled patients with locally advanced or metastatic prostate cancer. Patients received triptorelin (15 mg) intramuscularl…
-
206.
Several data support the efficacy/effectiveness, safety and favorable impact on quality of life of triptorelin treatment in patients with prostate cancer. However, little evidence is available concerning triptorelin use in the long term. We analyzed data on triptorelin treatment in patients with prostate cancer in an integrated Italian administrative database, covering around 6 million health-assisted subjects throughout the country. Patients with at least one prescription for triptorelin in the…
-
207.
We investigated the effects of the gonadotropin-releasing hormone (GnRH) agonist triptorelin as well the GnRH antagonist cetrorelix those of on the viability and steroidogenesis in human granulosa luteinized (hGL) cell cultures. The hGL cells were obtained from 34 women undergoing ovarian stimulation for IVF treatment. The cells were cultured for 48 h with or without 1 nM or 3 nM of cetrorelix or triptorelin in serum-free media. The cell viability was evaluated by the MTT [3-(4, 5-dimethylthiazo…
-
208.
In recent years, the conjugation of superparamagnetic iron oxide nanoparticles (SPIONs), as tumor-imaging probes for magnetic resonance imaging (MRI), with tumor targeting peptides possesses promising advantages for specific delivery of MRI agents. The objective of the current study was to design a targeted contrast agent for MRI based on Fe
-
209.
More than 100 patients with central precocious puberty are participating in this international multicenter study using monthly i.m. injections of the slow-release GnRH agonist Decapeptyl-Depot. In 15 patients, Decapeptyl-Depot treatment could be discontinued after 2 years of therapy. Gonadal suppression was promptly reversible in all of them, as shown by prepubertal low gonadotrophin- and sex steroid levels. Of the remaining 90 patients, 40 have been treated for more than 3 years, including 33 g…
-
210.
Metastatic prostate cancer is the most common malignant cancer and the second leading cause of death due to various types of cancer among men after lung cancer. This study aimed to analyze the cost-effectiveness of triptorelin, goserelin, and leuprolide in the treatment of the patients with metastatic prostate cancer from the societal perspective in Iran in 2020. This is a cost-effectiveness study in which a 20-year Markov transition modeling was applied. In this study, local cost and quality-of…
-
211.
The objectives of the current work were to develop a predictive population pharmacokinetic (PK)/pharmacodynamic (PD) model for the testosterone (TST) effects of triptorelin (TRP) administered in sustained-release (SR) formulations to patients with prostate cancer and determine the minimal required triptorelin serum concentration (C(TRP_min)) to keep the testosterone levels of the patients below or equal to the level of castration (TST ≤ 0.5 ng/ml). A total of eight healthy male volunteers and 74…
-
212.
To evaluate the cost-effectiveness of degarelix vs luteinizing hormone-releasing hormone analogue (triptorelin) plus short-term antiandrogen treatment for advanced prostate cancer. We developed a decision analytic model based on a clinical trial and literature review. The two interventions evaluated were: (i) monthly injection of degarelix and (ii) 3-monthly triptorelin therapy plus short-term flutamide, cyproterone or bicalutamide treatment. The model consisted of a decision tree monitoring a h…
-
213.
There are different opinions about the effect of body mass index on gonadotropin-releasing hormone stimulation tests in the laboratory diagnosis of precocious puberty in girls. The blood collection of precocious puberty girls with overweight or obesity is more difficult than those with normal body mass index. It is urgent to find non-invasive diagnostic methods for these girls. The purpose of the study was to evaluate the value of urinary gonadotropin after triptorelin stimulation tests for diag…
-
214.
Central precocious puberty (CPP) is typically treated with gonadotropin-releasing hormone (GnRH) agonists. Although numerous GnRH agonist variants are available, limited research has compared the efficacy of leuprolide acetate and triptorelin pamoate administered at 3-month intervals. This study aimed to assess the efficacy of CPP treatment with triptorelin pamoate and leuprolide acetate administered at 3-month intervals. This retrospective cohort study included 116 girls with CPP: 71 treated wi…
-
215.
In this study, the immunocytogenetic effects of Decapeptyl (Triptorelin Pamoate) were assessed in the peripheral blood lymphocytes of females undergoing in vitro fertilization (IVF) treatment. Blood samples were taken from 34 females (23 treated and 11 controls), cultured and examined for sister chromatid exchanges (SCE) and cell replication index (CRI). The SCE frequency increased around ovulation time in the controls, and around the time of human chorionic gonadotropin administration in the IV…
-
216.
The objective of this study was to evaluate the effects of exogenous GnRH administration at the beginning of estrus synchronisation in mares during the spring transitional period. Estrus was synchronised using a progesterone releasing intravaginal device (PRID). The PRID was left in the vagina for 10 days, followed by an injection of 0.4 mg of cloprostenol at PRID removal. The GnRH group (n = 32) was subjected to intramuscular administration of 100 μg of the GnRH agonist triptorelin at PRID inse…
-
217.
Two different 6-month GnRH agonist depot formulations approved for palliative treatment of advanced and metastatic prostate cancer in the United States - leuprolide acetate 45 mg and triptorelin pamoate 22.5 mg - provide patients with efficacy and safety comparable to those of existing 1-, 3-, and 4-month GnRH agonist depots. However, the 6-month formulations can increase patient convenience, comfort, and compliance by reducing the number of physician visits and injections required. At the concl…
- 218.
-
219.
<h4>Background</h4>Although triptorelin acetate (TA) is generally considered a safe medication, severe adverse drug reactions (ADRs) to triptorelin have occurred. In this study, we present the largest retrospective analysis of ADRs related to TA during the treatment of pediatric central precocious puberty.<h4>Methods</h4>We describe a total of 38 suspected cases of TA-induced ADRs reported to the pharmacovigilance center of Shenzhen Children's Hospital from September 2015 to December 2022. Causa…
-
220.
<h4>Background</h4>Adenomyosis negatively impacts fertility treatment outcomes by lowering clinical pregnancy rates, reducing live birth rates, and increasing miscarriage rates following in vitro fertilization. Hormonal suppression therapy has emerged as a preferred treatment for patients with adenomyosis, particularly before endometrial preparation for frozen-thawed embryo transfer; however, the combination therapy for individualized patients can improve the outcomes. Here we present three case…
-
221.
<h4>Objective</h4>To describe a rare case of ovarian hyperstimulation syndrome (OHSS) presenting as an isolated right-sided pleural effusion because of endogenous human chorionic gonadotropin (hCG) production from a naturally conceived pregnancy during a luteal-phase ovarian stimulation cycle.<h4>Design</h4>Single-patient case report with longitudinal follow up.<h4>Subject</h4>A healthy 36-year-old woman with a 15-month history of primary infertility who was undergoing her second luteal-phase ov…
-
222.
A 30-year-old woman with a body mass index of 20.6 kg/m² consulted due to two years of primary infertility. The patient had a history of two unsuccessful previous rounds of ovarian stimulation for IVF due to poor ovarian response. A novel ovarian stimulation approach incorporating luteal phase estradiol priming in a stop GnRH agonist plus delta follitropin-GnRH antagonist protocol was followed. <i>in vitro</i> fertilization was performed resulting in eight mature oocytes, which were fertilized a…
-
223.
<h4>Objectives</h4>To evaluate the clinical efficacy and safety of the 3-month formulation of triptorelin (triptorelin pamoate) in the treatment of idiopathic central precocious puberty (ICPP) in children.<h4>Methods</h4>A retrospective analysis was conducted of 49 children with ICPP treated with the 3-month formulation of triptorelin at Xiangya Hospital, Central South University, from May 2023 to September 2025. All patients received at least one injection and completed a 3-month follow-up. The…
-
224.
The limited availability of gonadorelin has resulted in an increased use of subcutaneous triptorelin to diagnose central precocious puberty; however, studies validating its diagnostic value remain limited. This study aimed to evaluate the usefulness of subcutaneous triptorelin stimulation testing for central precocious puberty evaluation. We retrospectively reviewed the medical records of 662 girls aged less than 8 years who were tested for central precocious puberty at the Ajou University Hospi…
-
225.
<h4>Objective</h4>The objective of this study is to investigate the individualized use of triptorelin in children diagnosed with central precocious puberty (CPP) and short stature.<h4>Methods</h4>Twenty-six children with CPP and short stature who received triptorelin treatment from June 2018 to May 2022 were included in the study. Treatment-related conditions, including treatment purpose, indications, protocols, monitoring and changes in predicted adult height (PHA), were summarized and analysed…
-
226.
<h4>Background</h4>This study aimed to compare the clinical efficacy of quarterly (15 mg/90 days) versus monthly (3.75 mg/28 days) triptorelin formulations with respect to bone maturation, predicted adult height (PAH), and hormonal suppression in Chinese girls with central precocious puberty (CPP).<h4>Methods</h4>This retrospective cohort study included 70 girls diagnosed with CPP at Fuzhou First General Hospital from March 2023 to 2025. Participants were assigned to either a quarterly regimen (…
-
227.
We aim to provide a translational model to investigate the reproductive consequences of pubertal delay using the GnRH agonist triptorelin in transgender girls, tested in particular on testicular maturation in peripubertal rats. A total of 30 Sprague Dawley rats were utilized, with 10 subjects assigned to each of three groups from day P30 postpartum (prepubertal) until day P95 (postpubertal), mimicking treatment timing in patients. Rats received triptorelin at three time points (P30, P50, and P71…
-
228.
Long-acting injectables (LAIs) have made a tremendous impact on clinical medicine. As evidence, dozens of approved LAI products are on the market. These LAI successes, in a large part, came from the clever chemistry of their materials that control drug delivery performance. Beyond their materials, what innovations and technologies led to LAI success? What were the scientific progressions and who were the people and their stories behind LAI success? The answers to these questions are interesting…
-
229.
<h4>Background and objectives</h4>Triptorelin acetate microspheres are long-acting gonadotropin-releasing hormone (GnRH) agonist used for treating central precocious puberty (CPP). GenSci006 is a newly developed 3.75-mg formulation intended as a local alternative to Diphereline<sup>®</sup>. This study aimed to characterize the pharmacokinetics (PK) of GenSci006 using population pharmacokinetic (PopPK) modeling with pediatric extrapolation, to evaluate pharmacodynamic (PD) comparability, and to s…
-
230.
<h4>Background</h4>Body mass index (BMI) may influence peak luteinizing hormone (PLH) levels during gonadotropin releasing hormone (GnRH) or GnRH analogues stimulation testing. BMI effects should be considered when interpreting test results for pubertal disorders in girls with overweight/obesity, but few studies have excluded it.<h4>Methods</h4>This was a hospital data-based retrospective study. Girls with puberty disorders who had been followed up for six months to two years were enrolled in th…
-
231.
<h4>Purpose</h4>To compare laboratory and embryological outcomes between dydrogesterone-based progesterone-primed ovarian stimulation (PPOS) and GnRH antagonist cycles when a GnRH agonist is used for final oocyte maturation in freeze-all IVF treatment.<h4>Methods</h4>This retrospective parallel cohort study included 795 stimulation cycles (718 antagonist, 77 PPOS) performed between May 2015 and September 2024 at ART Fertility Clinics UAE. All cycles used a GnRH agonist trigger (triptorelin 0.3 m…
-
232.
<h4>Background</h4>We present a rare and challenging case showing how an allergy to oral medications and cervical stenosis can complicate fertility treatment. The novelty lies in the exclusive use of injectable medications for both in vitro fertilization and frozen embryo transfer, the use of non-oral medications for luteal support, the off-label gonadotropin regimen for frozen embryo transfer stimulation, and the use of cervical dilatation to allow an atraumatic embryo transfer.<h4>Case present…
-
233.
<h4>Objectives</h4>Gonadotropin-releasing hormone agonists are used to suppress physical signs of puberty and improve height outcomes by decelerating bone age maturation in patients with central precocious puberty (CPP). Published data assessing biochemical and clinical parameters in patients with CPP treated with six-monthly triptorelin beyond 12 months is scant.<h4>Methods</h4>Thirty-seven girls with CPP were treated with 22.5 mg six-monthly intramuscular triptorelin. We assessed luteinizing h…
-
234.
<h4>Objective</h4>The aim of this study was to report three cases of early severe ovarian hyperstimulation syndrome (OHSS) in patients undergoing a GnRH antagonist protocol triggered with GnRH agonist (GnRH-a), leading to hospitalization and the need for peritoneal drainage. Additionally, a review of the existing literature on this topic is provided.<h4>Design</h4>This is a retrospective case series and a literature review.<h4>Setting</h4>This study was conducted at obstetrics and gynecology dep…
- 235.
- 236.
- 237.
-
238.
<h4>Background</h4>Central precocious puberty (CPP) is diagnosed through a combination of clinical, auxological, and biochemical parameters, with pharmacological stimulation tests considered the diagnostic gold standard. In recent years, triptorelin, a long-acting Gonadotropin-Releasing Hormone (GnRH) analog, has been increasingly adopted in clinical practice due to limited availability of native GnRH.<h4>Objective</h4>To compare the clinical, auxological, and hormonal profiles of girls diagnose…
-
239.
Abnormal follicular development during ovarian stimulation is a worrisome factor for the fertility specialist. Here, we report a unique case in which all the ovarian follicles developed in a synchronous but unusually accelerated pattern, posing an exceptional challenge. After starting the ovarian stimulation, we noticed follicles as large as 20 mm, 18 mm, and 17 mm on day 5 of stimulation. As most of the follicles grew to such an extent simultaneously, we named this pattern of follicular growth…
-
240.
Gonadotropin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.
<h4>Background</h4>Gonadotropin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent a luteinising hormone (LH) surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising the chances of live birth. We compared the benefits and risks of the different GnRHa protocols used.<h4>Objectives</h4>To evaluate the effectiveness and safety of different GnRHa protocols used as adjuncts to COH in women…
-
241.
<b>Objective:</b> To evaluate the efficacy and safety of triptorelin acetate microspheres for injection compared with triptorelin acetate for injection in the treatment of endometriosis. <b>Methods:</b> A total of 392 patients with endometriosis were prospectively enrolled from 47 research centers across China between October 25, 2021, and February 14, 2023. Participants were randomly assigned in a 1∶1 ratio to either the experimental group (<i>n</i>=196) or the control group (<i>n</i>=196). Bot…
-
242.
Hydrogen is a green energy carrier with high energy density. Its production and storage are facing challenges that have made researchers use different materials for its production and storage. Peptides are known to be very effective as the framework of metal cores for making electrocatalysts. Therefore, in this research, a network of nickel and copper with a peptide framework (PCuNi) was created on the surface of the graphite electrode by an electrochemical method, and then the performance of th…
-
243.
<h4>Background</h4>Prostate cancer (PC) is a common malignant tumor. Although androgen deprivation therapy (ADT) drugs are widely used in the treatment of PC, to date, clinical research on ADT drugs has not provided a clear overview of the existing treatment regimens. The purpose of this study is to use scoring review to sort out relevant research, present relevant research evidence, and identify recommended guidance for selecting therapeutic strategies.<h4>Methods</h4>PubMed, Embase and Cochran…
-
244.
<h4>Objective</h4>To expound the efficacy of Huayu Xiaozheng Decoction (HYXZD) combined with triptorelin and mifepristone in the treatment of uterine fibroids, with a particular focus on its effect on uterine artery hemodynamics.<h4>Methods</h4>A total of 102 women with uterine fibroids were enrolled and randomly allocated into a control group and an observation group. The control group received triptorelin plus mifepristone, while the observation group was additionally treated with HYXZD. Both…
-
245.
<h4>Background</h4>The relationship between gonadotropin-releasing hormone agonists (GnRH-as) and depression and suicide/self-injury (DASSI) remains controversial. This study aimed to investigate this potential association using data from the FDA Adverse Event Reporting System (FAERS) database.<h4>Methods</h4>Instances of DASSI linked with GnRH-as were identified from FAERS (2004Q1 to 2024Q1). Time-to-onset (TTO) analyses and disproportionality analysis (DPA) were employed to assess onset timing…
-
246.
<h4>Objectives</h4>Endometriosis-related dysmenorrhea and pelvic pain impose significant economic and quality-of-life burdens. This study evaluated the cost-effectiveness of dienogest compared to gonadotropin-releasing hormone agonists (GnRH-a) for managing dysmenorrhea and pelvic pain in Vietnam.<h4>Design</h4>The cost-effectiveness analysis using a Markov model was conducted from a healthcare payer perspective. Model input parameters were obtained from meta-analyses, published literature, and…
-
247.
<h4>Objective</h4>The objective of this study is to evaluate the effectiveness of prolonged GnRH agonist (GnRH-a) suppression combined with letrozole and intensive luteal phase support in a patient with severe adenomyosis undergoing frozen-thawed embryo transfer (FET).<h4>Design</h4>The study design was a case report.<h4>Setting</h4>The setting was a tertiary referral in vitro fertilization (IVF) clinic.<h4>Subjects</h4>The subject was a 41-year-old woman with a history of primary infertility wi…
-
248.
<h4>Background</h4>Fertility preservation is crucial for females facing gonadotoxic treatments. Controlled ovarian stimulation (COS) followed by oocyte cryopreservation is a well-established method, while ovarian tissue-derived oocyte in vitro maturation (OTO-IVM) is an emerging technique that can be used when COS is contraindicated or time is limited. However, OTO-IVM faces challenges such as low oocyte maturation rates and limited follow-up data. This study aimed to compare the clinical outcom…
- 249.
-
250.
<h4>Purpose</h4>Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.<h4>…
-
251.
Depression is a common comorbidity of chronic pain. Gonadotropin-releasing hormone (GnRH) and its receptor (GnRHR) expressed in the central nervous system are involved in non-reproductive functions. Herein, we aimed to elucidate the role and mechanism of action of GnRH in pain-related depression like behaviour in a mouse model. And we found that both GnRH and GnRHR were down-regulated in the anterior cingulate cortex of mice that were subjected to chronic pain-induced depression with complete Fr…
-
252.
Ovarian hyperstimulation syndrome (OHSS) is a serious complication of assisted reproductive technology (ART). Risk factors for OHSS include female age, polycystic ovarian morphology and high ovarian reserve. The use of a gonadotrophin-releasing hormone (GnRH) agonist trigger in a freeze-all cycle is an effective strategy for reducing the risk of OHSS in suspected high responders. Various GnRH agonist trigger preparations exist but their use is subject to manufacturer availability. The national s…
-
253.
Six-transmembrane epithelial antigen of prostate 2 (STEAP2) is overexpressed in prostate cancer, yet no STEAP2-targeted imaging probes exist. Using molecular docking, we screened triptorelin and leuprorelin by radioiodine labeling and identified triptorelin as a high-affinity, selective ligand. To enhance in vivo stability and pharmacokinetics, triptorelin underwent acetylation, PEG extension, and 4-iodophenylbutyric acid conjugation, yielding five DOTA-conjugated analogs radiolabeled with 68Ga.…
-
254.
Subcutaneous triptorelin stimulation testing is used to evaluate girls with early breast development when intravenous gonadotropin-releasing hormone is unavailable, but the optimal sampling times and minimum test duration remain uncertain. We retrospectively analyzed 186 girls younger than 8 years who presented with breast development and underwent subcutaneous triptorelin testing (0.1 mg), with serum luteinizing hormone (LH) and follicle-stimulating hormone measured at 0, 30, 60, 90, and 120 mi…
-
255.
Gonadotropin-releasing hormone agonists are used to treat central precocious puberty and are increasingly prescribed in gender-affirming care. Despite well-established reproductive effects, their broader physiological effects during puberty remain poorly understood. Male and female Wistar rats received a depot triptorelin injection at pubertal onset. Body mass, food intake, and locomotor activity were monitored. After 28 days, reproductive function was assessed, and pituitary and hypothalamic ge…
Preprints (not yet peer-reviewed)
3-
256.
<h4>Objectives: </h4> Despite the widespread use of the leuprorelin 3-month depot in central precocious puberty (CPP), its clinical efficacy and patient follow-up remain unexplored. This study aimed to compare the clinical indicators of the leuprorelin 3-month depot and triptorelin 1-month depot following treatment in a CPP cohort to understand the therapeutic effect of the former. <h4>Methods:</h4> A retrospective analysis was performed on 60 children diagnosed with progressive idiopathic CPP o…
-
257.
Recently, GnRHa puberty blockers have been under scrutiny, with newly identified risks of heart and brain damage and recurrent concerns about fertility, cancer risk, and bone health. This study explores the effects of GnRHa on liver morphology, function, and injury response. Peripubertal male and female Sprague-Dawley rats received daily GnRHa triptorelin (100 μg) subcutaneously. Liver oxidative stress, inflammation, and fibrosis were evaluated via malondialdehyde and 8-OHdG (oxidative damage),…
-
258.
<title>Abstract</title> <p> Suppression of pubertal hormonal signaling may alter trajectories of cortical development. However, the neurobiological effects of gonadotropin-releasing hormone agonists (GnRHa), including triptorelin, which are used in adolescents with gender dysphoria, remain largely unresolved. Here, we investigated how pubertal endocrine suppression influences brain development using a longitudinal in vivo translational model in which animals received long-acting triptorelin from…
Case Reports
7-
259.
The impacts of gonadtropin-releasing hormone (GnRH) agonists on thyroid function have long been observed and the conclusions were controversial. We here reported three cases of transient hyperthyroidisms after triptorelin therapy. The three patients showed decreased thyroid-stimulating hormone (TSH), with or without elevated free triiodothyronine (FT3) and free thyroxine (FT4) 2 weeks after injection of triptorelin. Thyroid-specific autoantibody assays showed antithyroid microsome autoantibody (…
-
260.
Central precocious puberty (CPP) is defined as the appearance of secondary sexual signs in girls younger than eight years of age or the onset of menarche before the age of 10 years. Gonadotropin-releasing hormone analogs (GnRHa) are the most effective therapy in CPP. Drug-induced hypersensitivity vasculitis is an inflammation of blood vessels, which may be due to the use of a number of pharmacologic agents. This case report describes drug-induced vasculitis in a girl being treated with Decapepty…
-
261.
Tamoxifen, a selective estrogen receptor modulator (SERM), can have harmful side effects, such as hypertriglyceridemia, which can lead to acute pancreatitis. Meanwhile, triptorelin is an analog of natural GnRH (GnRHa), which may cause a small but significant increase in cholesterol and triglyceride (TG) levels. We describe below the case of a patient with breast cancer treated with Patey's operation, chemo-radiotherapy, and then with tamoxifen and triptorelin. After an exposure period of three m…
-
262.
A case of allergic vasculitis of the skin following treatment with Decapeptyl (D-Trp6-LHRH) for in vitro fertilization is described. The possible role of an allergic mechanism in this reaction has been suggested by a positive macrophage migration inhibition factor (MIF) test toward the drug.
-
263.
We report a case of a patient diagnosed with pulmonary endometriosis and successfully treated with a GnRH agonist. This 34-year-old mother presented cyclic hemoptysis since 4-month. A non-enhanced computed tomography made at the end of the luteal phase revealed a solitary lung nodule with no other abnormalities. A contrast enhanced computed tomography conducted during menses revealed a ground glass opacity extending from the nodule towards hilum. The diagnosis of pulmonary endometriosis was esta…
-
264.
Gonadal dysfunction is a well-known endocrine manifestation of Down syndrome (DS) in men. Herein, we report a case of a seven-year-old boy with DS who developed precocious puberty, presenting with a six-month history of frequent erections, sudden growth spurts, and adult odors. Clinical examination revealed stage 2 puberty, with pubic hair development at stage 2 based on Tanner staging and bilateral testicular volumes of 6 mm. Laboratory tests indicated elevated luteinizing hormone (LH) and foll…
-
265.
Functional gonadotropic adenoma is a rare pituitary adenoma. Only a few cases have been reported. Herein, we describe the case of a 30-year-old Chinese woman with functional gonadotroph adenomas (FGAs) with relative hyperprolactinemia and no obvious neurologic signs. Ovarian hyperstimulation due to a follicle-stimulating hormone (FSH)-secreting adenoma was observed after treatment with a gonadotropin-releasing hormone analogue (GnRH-a). The patient was successfully treated through pituitary aden…
Curated sources on file
32- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.